DLT and RP2D
EVENTS
 Among the 12 patients in the phase I study, 10 met the requirements for inclusion in the dose-determining set, including 6 patients in the 200-mg dose group and four patients in the 300-mg dose group. All 10 patients completed the DLT assessment and no DLT events were observed. The RP2D was determined to be 300 mg QD orally.